Viking Therapeutics and the Clinical Milestones Shaping Its 2028 Outlook
Viking Therapeutics is advancing multiple late-stage trials for its flagship drug candidate, VK2735, with critical readouts anticipated between 2027 and 2028 that could heavily influence its long-term valuation.
🧠AI AnalysisPhoto: Motley Fool
Key points
- Viking Therapeutics has four phase 3 trials underway for its VK2735 drug.
- Data for oral trials are expected in 2028 following 68-week observation periods.
- Analysts estimate risk-adjusted peak sales could reach $3.5 billion under favorable conditions.
Viking Therapeutics is currently running four phase 3 clinical trials for its primary drug, VK2735, targeting obesity and obesity with type 2 diabetes. The company's development pipeline includes both subcutaneous injection versions and oral formulations.
While the injectable trials aim to establish market footing against established industry leaders like Eli Lilly and Novo Nordisk, the oral trials are designed to broaden the potential addressable market. A dual-formulation strategy could allow patients to transition from an initial injectable dose for rapid weight reduction to a more manageable oral maintenance routine.
Clinical data for the subcutaneous trials, designated Vanquish-1 and Vanquish-2, are projected for the second half of 2027. Meanwhile, the oral trials, Sunrise-1 and Sunrise-2, commenced recently and span 68 weeks, with results anticipated in 2028. Additionally, maintenance trial data is slated for release in 2027.
Financial projections suggest that if the drug successfully captures a meaningful share of the lucrative weight-loss market—pegged by data analytics firm Evaluate at up to $70 billion for competing treatments by 2032—risk-adjusted peak sales for VK2735 could reach $3.5 billion. Such figures imply significant upside potential for early investors depending on regulatory success and trial efficacy.
What to watch next: Monitor upcoming updates on the subcutaneous maintenance trial expected in 2027, as well as patient discontinuation rates and tolerability data.
Source Motley Fool — fool.com/investing/2026/11/13/predict-10k-invested-viking-therapeut… ↗
Read next
🏢CompaniesModine Manufacturing Shares Jump 23% on Potential Acquisition Talks With Samsung
Modine Manufacturing shares surged nearly 23% in premarket trading following reports that Samsung Electronics is discussing an acquisition of the U.S. data center cooling…
💼InvestingThree Dividend Stocks to Consider As Market Valuations Echo the Dot-Com Era
With the S&P 500 Shiller CAPE ratio reaching levels not seen since late 1999 and early 2000, everyday investors are searching for reasonably priced equities with reliable…
🧠AI AnalysisExxonMobil Increases Dividend to $1.07: What It Costs to Generate $1,000 a Month
ExxonMobil raised its quarterly dividend by 3.9% to $1.07 per share, extending its dividend growth streak to 44 consecutive years. Investors seeking $1,000 in monthly pay…
🧠AI AnalysisHomeowners Take Control of Heat Pump Calculations Amid Rising Demand
As interest in heat pumps grows across the US, a rising number of private homeowners are turning to specialized software like Cool Calc to independently verify property h…
🧠AI AnalysisEast Side Games Group Focuses on Cash Discipline and Capital Efficiency in Q3
East Side Games Group reported its third-quarter 2026 financial results, highlighting strict cash management and reduced user acquisition spending.
🧠AI AnalysisFederal Reserve Reforms Led by Chair Kevin Warsh Ignite Bond Market Volatility
Federal Reserve leadership changes under Chair Kevin Warsh have removed forward-looking guidance, pushing 30-year Treasury yields to their highest levels since 2002.